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Abstract
The aim of this study is to find out the outcome of 28 patients who got the diagnosis of primary fibromyalgia (pFM) 26 years ago.
In 1986, 56 patients with widespread pain were examined and filled in a base questionnaire (BQ). Of them, 42 fulfilled the Yunus
criteria for pFM. Twenty-six years later, addresses of 38 patients were found, and an extensive follow-up questionnaire (FupQ)
was mailed to them. Of them, 28 (74%) answered the FupQ. This included nine identical questions with the BQ and questions
concerning changes in their symptoms and quality of life (Qol). Three patients (11%) had healed from fibromyalgia (FM), and
23% reported having one or several symptomless periods lasting at least 1 year. In others (n = 25), all but pain and ache showed
slight deterioration. Despite the aging and FM, the level of functional ability evaluated by Stanford Health Assessment
Questionnaire (HAQ) remained at the same level (BQ 0.41 vs. Fup 0.44, p = 0.82). The sum score of reported symptoms (n =
21) did not change significantly (10.8 (SD 2.9) vs. 11.1 (SD 4.1), p = 0.75). Experienced sleeplessness increased most signifi-
cantly (27 vs. 65%, p = 0.0034). Exercising did not have a significant influence on the changes of the measured parameters.
However, the three healed patients exercised regularly. Symptoms of FM have persisted in most patients for decades without
significant deterioration of self-reported functional ability. About one fourth of patients had experienced long symptomless
periods during their illness. Three patients (11%) reported that they have healed from FM.
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Introduction
Fibromyalgia (FM) represents one of the syndromes in which
central sensitization (CS) plays a great role [1, 2]. The syn-
drome seems to be persistent, but also remissions have been
seen in follow-up (Fup) studies [3].
There are quite few long-term follow-up studies (FupS)
concentrating on the clinical course of FM and lasting 6 years
or more [3–10]. Symptoms usually persist but patients learn to
cope with them and become slightly better [4–5, 7–8,].
Fluctuation of symptoms was found in the longest FupS.
Sometimes, the participants did not fulfill the FM criteria as
44% of patients, initially criteria-positive, failed to meet
criteria at least once during 11–16.5-year Fup time. At the
end of the study, 25% of patients had at least moderate im-
provement of pain but 36% of patients felt their situation
worsen [9]. Active training and participation in patient educa-
tion programs seem to give better prognosis [6].
The longest reported Fup periods have been 19 and
35 years. Of these studies, the first one concentrated on work-
ing ability [11] and the second one on mortality [12]. Thus,
there is a need for reports of the very long-term outcome of
FM.
The aim of this study was to find out and describe the
outcome of 28 patients who got the diagnosis of primary fi-
bromyalgia (pFM) 26 years before the study, in 1986.
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Material and methods
In 1986 at the Rheumatism Foundation Hospital (RFH),
Heinola, Finland, we collected data from 56 patients with
widespread pain (WSP). They fulfilled a questionnaire with
25 questions and were clinically examined by a rheumatolo-
gist or a physiatrist (RI) including the tender point (TP) count.
Of them, 42 fulfilled the diagnosis of primary fibromyalgia
(pFM) according to Yunus 1981 [13].
The structured questionnaire included questions about con-
comitant diseases, social situation, work, and about patient’s
symptoms and factors which relieve or worsened them (e.g.,
effects of weather changes, sauna, medication, given physio-
therapy, and their self-treatment methods). The baseline ques-
tionnaire (BQ) included pain rating in 100 mm visual analog
scale (VAS), Stanford Health Assessment Questionnaire
(HAQ) [14], and a Finnish questionnaire to evaluate depres-
sion briefly by Rimon (RBDS) [15]. After the baseline study
visit in RFH, the patients continued their treatment and con-
trols with their local doctors.
The FupS was done as a postal questionnaire 26 years after
the baseline examination. We asked the addresses of the 42
patients with definite FM from the Finnish population registry.
We got the addresses of 38 patients; the four missing patients
had either emigrated from Finland or died. The follow-up
questionnaire (FupQ) was mailed to those 38 patients in
November 2012 and a second mailing was done in February
2013 for those who had not responded to the first contact.
The FupQ included 52 questions. Nine questions were
identical with the base questionnaire (BQ). These were marital
status, other diseases, factors affecting negatively on life, 25
different symptoms, pain rating in 100 mm VAS (last
3 months), RBDS, HAQ, and effects of weather changes and
sauna on the patient’s symptoms and general feelings. In sev-
en questions, we asked the patients to estimate with a five-
point Likert scale the changes in their FM symptoms and
general feelings during the 26-year Fup time. The patients
were asked to focus their interest only towards FM symptoms,
when they were answering these questions. Furthermore, their
body mass index (BMI) was calculated from their self-
reported height and weight. They filled in the Fibromyalgia
Impact Questionnaire (FIQ) [16] and EuroQol-5 D [17]. In
EQ-5D, we used only 200 mm line with 1–100 scale.
The study plan was accepted in the Regional Ethics
Committee of the Expert Responsibility Area of Tampere
University Hospital on September 4, 2012.
Statistical analysis
Statistical comparison of changes in outcome measurements
was performed by using the Fisher-Pitman permutation test
for paired replicates and exact McNemar test. Confidence
intervals for the means changes were obtained by bias-
corrected bootstrapping (5000 replications). Correlations were
estimated with Spearman’s correlation coefficient method.
Statistical analyses were performed using the Stata statistical
software, release 13.0 (StataCorp, College Station, TX, USA).
Results
We got relevantly filled FupQ from 28 of the 38 patients
(74%). The symptoms of the patients had lasted on average
6 years before the baseline examination when the diagnosis of
pFM was conducted in the RFH in 1986 (Table 1). The TP
count of the FupQ group was 11.5 (SD 3.3) at baseline. This
did not significantly differ from those patients (n = 14) which
did not respond the FupQ. In 1986, when patients were exam-
ined, the minimum TP count needed for diagnosis of FM was
5 points by Yunus criteria 1981.WSP consistent with the
criteria of ACR-90 diagnosis [18] was reported in the Fup
stage by 26 (93%) patients. The FIQ mean total score was
43 (SD 13).
One or several symptomless periods lasting more than
1 year were reported by 6/26 (23%) of patients who answered
the question. Three of them (11%) answered that they had




Female, n (%) 26 (93)
Age, years, mean (SD) 70 (9)
Living alone, n (%) 4 (14)
FM symptoms, years, mean (SD) 32 (7)
Body mass index, mean (SD) 27.8 (3.7)
Widespread pain *, % (95% CI) 93% (76–99)
EQ5D **, mean (SD) 59 (22)
FIQ, mean (SD)
FIQ total score 43 (13)
Physical function 1.8 (1.9)
Feel good 4.2 (2.9)
Work missed 2.2 (3.1)
Job ability 6.9 (1.5)
Pain 6.8 (1.5)
Fatigue 5.1 (2.3)




*Like in ACR—90 criteria
**Scale 0–100 (0 = the worst health, 100 = the best health)
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healed from fibromyalgia. The symptomless period of these
patients had been 25, 10, and 2 years before the FupS.
Pain and ache during the last 3 months measured by
100 mm VAS was in the Fup 61 mm. Reported pain (Fig. 1)
did not correlate with the patients age nor with their BMI.
Altogether, 48% reported restless legs syndrome (RLS) symp-
toms weekly.
The number of symptoms did not change significantly be-
tween the baseline and FupS. The sum score of reported 21
symptoms was in the beginning 10.8 (SD 2.9) and at the end
11.1 (SD 4.1), p = 0.75. The frequencies of the following
symptoms showed significant changes at Fup: less pain during
nighttime in the Fup (BQ% vs. FupQ%) 62 vs. 27% (p =
0.035), more abdominal irregularities in the Fup (31 vs.
65%, p = 0.035), and more sleeplessness (27 vs. 65%, p =
0.0034). The most common symptoms which were reported
by the same patient both at the baseline and at Fup were
morning stiffness (n = 23), influence of weather changes on
symptoms (n = 23), pain during movements (n = 18), numb-
ness and tightness of muscles (n = 15), and general fatigue
(n = 13).
In identical questions (BQ vs. FupQ), significant differ-
ences were not found in the following: pain by VAS was 52
vs. 61 mm, RBDS 8.6 vs. 6.8, HAQ 0.41 vs. 0.44, the wors-
ening effect of weather changes 89 vs. 96% and sauna 71 vs.
80% (Table 2). The age of patients did not associate in the Fup
with RBDS (p = 0.36), HAQ (p = 0.087), or FIQ (p = 0.78).
The experienced level of function (HAQ) also did not associ-
ate with pain VAS (p = 0.56) or with the FIQ total scores (p =
0.097) in the Fup.
Figure 2 shows changes in the main symptoms and in the
quality of life. In general, all but pain and ache showed slight
deterioration, but a lot of symptom specific variance did occur.
The age or baseline TP count of patients did not associate
significantly with these changes. The amount of reported ex-
ercise by the patients did not explain the differences between
these groups (improved, unchanged, worsened), either. The
three Bhealed^ patients did not answer these questions.
The following diagnoses of other major illnesses were con-
ducted for the patients during the follow-up time:
osteoarthrosis (n = 13), chronic back pain (6), hypothyreosis
(6), cardiac disease (6), bronchial asthma (6), diabetes mellitus
(3), breast cancer (2), rheumatoid arthritis (1), ankylosing
spondylarthritis (1), and Sjögren’s syndrome (1). No one re-
ported depression.
Regular exercise was practiced by 21/24 (88%) of patients
answering the question. Nine out of twenty (45%) participants
reported exercising at least three times a week. In the Fup, the
exercise did not explain the variance of the following mea-
surements: pain VAS, RBDS, HAQ, or FIQ. It also did not
explain the changes in symptoms and quality of life or the
amount of symptomless periods during the 26-year period
reported by the patients. Those three patients who had report-
ed having healed from FM stated exercising regularly at least
1–2 times a week.
The use of pain medication had decreased with 31% of
patients, remained unchanged with 8%, and increased with
61%. The patients reported that the three best pain medica-
tions were paracetamol (35%), ibuprofen (35%), and a com-
bined preparation containing 500 mg paracetamol + 30 mg
codeine (9%). The four best drugs improving sleep were
zopiclone (31%), amitriptyline (15%), zolpidem (15%), and
a preparation containing 12.5 mg amitriptyline + 5 mg chlor-
diazepoxide (15%). Vitamins, mineral supplements, and nat-
ural health products were used by 22/28 (79%) patients. Self-
care (yoga, exercise, etc.) was practiced by all patients (n =
28). The best self-treatment methods were exercise 18/27
(66%), winter swimming 4/27 (15%), and relaxation methods
2/27 (7%).
Discussion
This prospective study examined the long-term outcome of
patients with pFM diagnosed 26 years ago. The follow-up rate
was rather good (74%) for such a long Fup. FM persisted in
most of the patients, while three (11%) reported that they had
healed from FM. In addition, about quarter reported that they
had had at least one symptomless period lasting at least 1 year
or more.
Those patients (n = 25) whose symptoms continued report-
ed slight deterioration of symptoms, but they were also
26 years older than at baseline (Fig. 2). However, less night
Fig. 1 Pain measured by visual analogue scale (VAS) by the patients’ age
at follow-up
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pain was reported in the Fup, whereas sleeplessness and ab-
dominal irregularities were more common in the Fup. The
level of functional ability evaluated by HAQ remained at the
same level at the baseline and the Fup. This means that al-
though the symptoms persist, the worsening of self-evaluated
functional ability did not occur. The patients were 26 years
older in the Fup, and thus, the good HAQ result was a positive
surprise. Functional ability, analyzed byFinnFIQ,was better in
this study than in a previous Finnish study [16]. Patients may
adapt to their symptoms in a long run.
As in our study, FM has been rather persistent in other
FupS, too. Bengtsson et al. [3] found that only 1 of 55 patients
had healed at 8-year follow-up.Wallit [9] reported that 10% of
patients were almost symptom-free at a 16.5-year follow-up,
which is comparable to our result (11%).
In general, symptoms of FM may fluctuate [9], which
may cause false positive results in short-term outcome
studies [19]. The fluctuation was seen also in our 26-year
FupS as every fourth reported at least one ore more pain-
free periods. This strengthens the importance of long
follow-up studies.
Deterioration of symptoms was more common in our study
than in previous long-term clinical studies (over 6 years)
[3–10]. However, the sum score of symptoms did not show
worsening. This supports the previous findings that various
symptoms persist [5, 7, 8, 20]. On the other hand, it should be
remembered that country-specific issues, such as different
compensation systems, may influence the patient’s outcome
[21].
Almost half of the subjects reported symptoms of RLS, but
only one had that diagnosis. In a previous study, the preva-
lence of RLS was 33% among FM patients [22], whereas it
varies from 2 to 15% among the normal population [23]. The
symptoms of RLS should be asked from FM patients and
evaluate whether diagnostic examinations are needed.
Treatment of RLS, when needed, could improve sleep and
quality of life [22].
The effect of weather changes on the patients’ symptoms
was very high in our study [24, 25]. Few studies have shown
correlation between air pressure and FM symptoms [24, 26],
and those whose symptoms have persisted less than 10 years
show stronger reactions [27].
Table 2 Changes in symptoms
and measurements between
baseline and follow-up contacts





Pain, VAS (SD) 52 mm (20) 61 (21) NS
Sleeplessness 25% 68% p = 0.0034
Negative effect of sauna (L4 + 5)* 71% 80% NS
Effect of weather changes (L4 + 5)* 89% 96% NS
RBDS (SD)** 8.6 (4.6) 68 (4.4) NS
HAQ (SD)*** 0.41 (0.36) 0.44 (0.49) NS
*Measured by Likert scale 1–5; L4 = gets worse slightly, L5 = gets a lot worse
**Rimon’s brief depression scale (see text)
***Health Assessment Questionnaire (see text)
Fig. 2 Reported changes in symptoms during 26-year follow-up
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The worsening effect of sauna to FM symptoms has been
reported by clinicians in Finland [28], where most people
enjoy sauna (temperature 70–100 °C) regularly. Sauna is a
heat stress for the body, and stress may modulate symptoms
in FM [29].
Exercising is important to FM patients [30]. In addition to
diminishing pain, cardiovascular fitness training showed acti-
vation on brain areas responsible of painmodulation [31]. Most
of the patients (21/24) in our FupS reported that they exercise
regularly. This may have kept their self-reported functioning
(HAQ) at the same level as at baseline, although their symp-
toms showed slight worsening. However, more than half had
increased their use of pain medication from the baseline.
Probably, the medication relieved not only FM symptoms but
also pain caused by age-related degenerative changes.
Although the strength of our study is the long follow-up,
our study has several weaknesses. The number of patients was
small, and they represent secondary or tertiary care popula-
tion. The diagnostic criteria of FM have changed during the
follow-up although as many as 93% fulfilled the criteria for
WSP (ACR-90) at the follow-up. On the other hand, the base-
line FM diagnoses were solid (confirmed by the same experi-
enced clinician [RI] who performed the FuoQ), and most of
the patients replied to the FupQ.
We conclude that this study shows that in most cases the FM
symptoms persist for years and even decades. However, the
symptoms fluctuate and patients may have long symptomless
periods and 11% even reported that they have healed from FM.
We did not find any explanations to the poor or good outcome,
but most of our patients performed physical exercise regularly.
When a patient with FM asks about her/his future, we have
to tell that the symptoms are likely to remain, but will probably
fluctuate so that even long symptomless periods may take
place. Healing of the problem is possible, however rather un-
common. Patients should be encouraged to engage in physical
exercise, since it will keep on the physical ability to do daily life
activities (HAQ remained here unchanged), although physical
exercise will probably not make the symptoms disappear.
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